• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

BMC. Ethyl pyruvate reduces mortality in an endotoxin-induced severe acute lung injury mouse model

Giuseppe

Emeritus
Ethyl pyruvate reduces mortality in an endotoxin-induced severe acute lung injury mouse model (BMC, Abstract, edited)

Ethyl pyruvate reduces mortality in an endotoxin-induced severe acute lung injury mouse model

Guan-Hong Shang, Dian-Jie Lin, Wei Xiao, Chong-Qi Jia, Yu Li, Ai-Hua Wang, Liang Dong and Guan-Hong Shang
Respiratory Research 2009, 10:91
doi:10.1186/1465-9921-10-91
Published: 2 October 2009


Abstract (provisional)

Background
Ethyl pyruvate (EP) was recently identified as an experimental therapeutic agent in a wide variety of model systems for inflammation-mediated tissue and cellular injury.

Objective
To evaluate the effect of ethyl EP on improving the survival in mice with LPS-induced acute lung injury (ALI).

Methods
ALI was induced by administering lipopolysaccharide (LPS) intratracheally. The mice were treated intraperitoneally (i.p.) with 100, 50 and 10 mg/kg EP immediately before intratracheal instillation of LPS, and 100 mg/kg EP was administered 0, 12, 24 and 48 hours after induction of ALI. The mortality rate was recorded and analyzed by the Kaplan-Meier method. Serum tumor necrosis factor (TNF)-alpha, interleukin (IL) -6 and IL-1 beta were measured in bronchial alveolar lavage fluid using an enzyme-linked immunosorbent assay. High-mobility group box 1 levels were measured by Western immunoblotting.

Results
Treatment with EP significantly inhibited the release of HMGB1, TNF-alpha, IL-6 and IL-1beta into bronchoalveolar lavage (BAL) fluids of ALI mice, and reduced the permeability index of the injured lung. High EP doses reduced the mortality from ALI and the permeability index (100mg/kg and 50mg/kg EP versus control; P < 0.0001). Early administration of high-dose EP significantly increased survival rate (0, 12 and 24 h versus control; P < 0.0001, P <0.0001 and P = 0.01 respectively by log-rank test). There was no survival advantage when EP was initiated at 48 h.

Conclusions
Ethyl pyruvate improves survival and reduces the lung permeability index in mice with LPS-induced ALI.
-
<cite cite="http://respiratory-research.com/content/10/1/91">Abstract | Ethyl pyruvate reduces mortality in an endotoxin-induced severe acute lung injury mouse model</cite>
 

Attachments

Back
Top Bottom